van Eupen Marcelle G A, Schram Miranda T, Colhoun Helen M, Scheijen Jean L J M, Stehouwer Coen D A, Schalkwijk Casper G
Department of Internal Medicine, Maastricht University Medical Centre (MUMC) and Cardiovascular Research Institute Maastricht (CARIM), Universiteitssingel 50, Maastricht 6200, MD, the Netherlands.
Cardiovasc Diabetol. 2013 Oct 17;12:149. doi: 10.1186/1475-2840-12-149.
Advanced glycation endproducts (AGEs) may play a role in the development of coronary artery calcification (CAC) in type 1 diabetes (T1DM). We studied plasma AGEs in association with T1DM and CAC, and whether or not the latter association could be explained by low-grade inflammation (LGI) or endothelial dysfunction (ED).
We studied 165 individuals with and 169 without T1DM. CAC was quantified in a CAC score based on CT-scanning. Plasma levels of protein-bound pentosidine, Nϵ-(carboxymethyl)lysine (CML) and Nϵ-(carboxyethyl)lysine (CEL) were measured with HPLC/UPLC with fluorescence detection or tandem-mass spectrometry. Tetrahydropyrimidine (THP) was measured with ELISA, as were HsCRP, and sVCAM-1 and vWF, as markers for LGI and ED, respectively. Associations were analyzed with ANCOVA and adjusted for age, sex, BMI, waist-to-hip ratio, smoking, blood pressure, lipid profile, eGFR and T1DM.
Individuals with T1DM had higher plasma levels of pentosidine, CML and THP compared with controls; means (95% CI) were 0.69 (0.65-0.73) vs. 0.51 (0.48-0.54) nmol/mmol LYS, p < 0.001; 105 (102-107) vs. 93 (90-95) nmol/mmol LYS, p < 0.001; and 126 (118-134) vs. 113 (106-120) U/mL, p = 0.03, respectively. Levels of pentosidine were higher in individuals with T1DM with a moderate to high compared with a low CAC score, means (95% CI) were 0.81 (0.70-0.93) vs. 0.67 (0.63-0.71) nmol/mmol LYS, p = 0.03, respectively. This difference was not attenuated by adjustment for LGI or ED.
We found a positive association between pentosidine and CAC in T1DM. These results may indicate that AGEs are possibly involved in the development of CAC in individuals with T1DM.
晚期糖基化终产物(AGEs)可能在1型糖尿病(T1DM)患者冠状动脉钙化(CAC)的发生发展中起作用。我们研究了血浆AGEs与T1DM及CAC的关系,以及后者之间的关联是否可由低度炎症(LGI)或内皮功能障碍(ED)来解释。
我们研究了165例T1DM患者和169例非T1DM患者。基于CT扫描的CAC评分对CAC进行定量。采用高效液相色谱/超高效液相色谱结合荧光检测或串联质谱法测定血浆中蛋白结合的戊糖苷、Nε-(羧甲基)赖氨酸(CML)和Nε-(羧乙基)赖氨酸(CEL)水平。采用酶联免疫吸附测定法(ELISA)测定四氢嘧啶(THP),同时测定超敏C反应蛋白(HsCRP)、可溶性血管细胞黏附分子-1(sVCAM-1)和血管性血友病因子(vWF),分别作为LGI和ED的标志物。采用协方差分析(ANCOVA)分析相关性,并对年龄、性别、体重指数、腰臀比、吸烟、血压、血脂谱、估算肾小球滤过率(eGFR)和T1DM进行校正。
与对照组相比,T1DM患者血浆中戊糖苷、CML和THP水平更高;平均值(95%可信区间)分别为0.69(0.65 - 0.73)对0.51(0.48 - 0.54)nmol/mmol赖氨酸,p < 0.001;105(102 - 107)对93(90 - 95)nmol/mmol赖氨酸,p < 0.00;126(118 - 134)对113(106 - 120)U/mL,p = 0.03。与低CAC评分的T1DM患者相比,中度至高度CAC评分的T1DM患者戊糖苷水平更高,平均值(95%可信区间)分别为0.81(0.70 - 0.93)对0.67(0.63 - 0.71)nmol/mmol赖氨酸,p = 0.03。校正LGI或ED后,这种差异并未减弱。
我们发现T1DM患者中戊糖苷与CAC之间存在正相关。这些结果可能表明AGEs可能参与了T1DM患者CAC的发生发展。